These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 693521)

  • 21. Acute tolerance to barbiturate in the rat.
    Turnbull MJ; Watkins JW
    Eur J Pharmacol; 1976 Mar; 36(1):15-20. PubMed ID: 944131
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differential selectivity of several barbiturates on experimental seizures and neurotoxicity in the mouse.
    Raines A; Blake GJ; Richardson B; Gilbert MB
    Epilepsia; 1979 Apr; 20(2):105-13. PubMed ID: 37070
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Physical dependence to barbital compared to pentobarbital. III. Withdrawal characteristics.
    Boisse NR; Okamoto M
    J Pharmacol Exp Ther; 1978 Mar; 204(3):514-25. PubMed ID: 564952
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Physical dependence to barbital compared to pentobarbital. I. "Chronically equivalent" dosing method.
    Boisse NR; Okamoto M
    J Pharmacol Exp Ther; 1978 Mar; 204(3):497-506. PubMed ID: 564950
    [No Abstract]   [Full Text] [Related]  

  • 25. Effect of chronic pentobarbital treatment on the development of cross-tolerance to ethanol and barbital.
    Khanna JM; Lê AD; Gougos A; Kalant H
    Pharmacol Biochem Behav; 1988 Sep; 31(1):179-86. PubMed ID: 3252249
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Osmotic minipumps for administration of barbital to mice: demonstration of functional tolerance and physical dependence.
    Siew C; Goldstein DB
    J Pharmacol Exp Ther; 1978 Mar; 204(3):541-6. PubMed ID: 564954
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of ethanol and barbiturate physical dependence.
    Okamoto M; Hinman DJ; Aaronson LM
    J Pharmacol Exp Ther; 1981 Sep; 218(3):701-8. PubMed ID: 7196450
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of NMDA antagonists on development of rapid tolerance to various barbiturates.
    Khanna JM; Kalant H; Chau A; Shah G
    Alcohol; 1998 Jan; 15(1):9-18. PubMed ID: 9426832
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Induction time measurement of barbital tolerance in mice given recurrent subhypnotic dosage of barbital.
    Risher DL; Baccus AL; Townsend SW; Proctor CD
    J Natl Med Assoc; 1982 Dec; 74(12):1183-7. PubMed ID: 7154102
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Continuous administration of barbital by pellet implantation.
    Flint BA; Ho IK
    J Pharmacol Methods; 1980 Sep; 4(2):127-39. PubMed ID: 7192783
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sulfolane-induced convulsions in rodents.
    Andersen ME; Jones RA; Kurlansik L; Mehl RG; Jenkins LJ
    Res Commun Chem Pathol Pharmacol; 1976 Nov; 15(3):571-80. PubMed ID: 825938
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Barbital alteration of central nervous system sensitivity to hexobarbital in the rat.
    Schnell RC; Stoll RE; Prosser TD
    Psychopharmacology (Berl); 1976 May; 47(1):93-6. PubMed ID: 959468
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Similar development of tolerance to barbital-induced inhibition of avoidance behavior and loss of righting reflex in rats.
    Richter JA; Harris PS; Hanford PV
    Pharmacol Biochem Behav; 1982 Mar; 16(3):467-71. PubMed ID: 7079283
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effects of atropine on the tolerance and the convulsions seen after withdrawal from forced barbital drinking in the rat.
    Wahlström G
    Psychopharmacology (Berl); 1978 Oct; 59(2):123-8. PubMed ID: 103112
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interaction of hydralazine with barbiturates.
    Czyzewska-Szafran H; Wutkiewicz M
    Pol J Pharmacol Pharm; 1977; 29(4):347-57. PubMed ID: 905202
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development of tolerance to chronic barbital treatment in the cerebellar cyclic guanosine monophosphate system and its response to subsequent barbital abstinence.
    Lane SJ; Morgan WW
    J Pharmacol Exp Ther; 1985 Sep; 234(3):569-74. PubMed ID: 2993585
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of p-chlorophenylalanine on the acquisition of tolerance to the hypnotic effects of pentobarbital, barbital, and ethanol.
    Khanna JM; Kalant H; Lê AD; Mayer J; LeBlanc AE
    Can J Physiol Pharmacol; 1980 Sep; 58(9):1031-41. PubMed ID: 6450628
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antiextensor effects of 3,3-diphenyl-n-propylamine in the mouse.
    Helke CJ; Raines A
    Eur J Pharmacol; 1978 Apr; 48(3):231-5. PubMed ID: 639851
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Changes in convulsion threshold and changes in the action of certain sleep-inducing drugs in hypertensive rats (DOCA/NaCl and SHR).
    Czyzewska-Szafran H
    Acta Physiol Pol; 1980; 31(2):147-52. PubMed ID: 7395539
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A model for the rapid development of tolerance to barbiturates.
    Ho IK; Sutherland VC; Loh HH
    Res Commun Chem Pathol Pharmacol; 1973 Jul; 6(1):33-46. PubMed ID: 4734011
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.